Research Grade Lutikizumab (DHB95502)

Catalog No.

DHB95502

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Humanized

Isotype

IgG1-kappa (DVD-Ig)

Clonality

Monoclonal

Target

IL1F1, Interleukin-1 alpha, IL1A, Hematopoietin-1, IL-1 alpha, Interleukin-1 beta, IL1B, Catabolin, IL1F2, IL-1 beta

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P01583 & P01584

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

Bispecific, ABT-981, CAS: 1791411-57-8

Clone ID

Lutikizumab

A Phase II Trial of Lutikizumab, an Anti-Interleukin-1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis, PMID: 30653843

Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date, PMID: 31916225

Is Lutikizumab, an Anti-Interleukin-1 α/ β Dual Variable Domain Immunoglobulin, efficacious for Osteoarthritis? Results from a bayesian network meta-analysis, PMID: 33204726

Osteoarthritis year in review 2019: epidemiology and therapy, PMID: 31945457

Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis, PMID: 30552176

Document Download

Research Grade Lutikizumab.pdf